Professional Documents
Culture Documents
The Drug Treatment of Alcohol Withdrawal Symptoms: A Systematic Review
The Drug Treatment of Alcohol Withdrawal Symptoms: A Systematic Review
The Drug Treatment of Alcohol Withdrawal Symptoms: A Systematic Review
103-115, 1998
REVIEW
Abstract — A computer-assisted and cross-reference literature search identified trials of therapy for
alcohol withdrawal symptoms. Those with a randomized, double-blind placebo-controlled design were
systematically assessed for quality of methodology. Fourteen studies were identified investigating 12
different drugs. The quality of methodological design, even among this highly selected group of
published studies, was often poor. Study populations were generally under-defined, most studies
excluded severely ill patients, control groups were poorly matched, and the use of additional medication
may have confounded results in some studies. Twelve different rating scales were used to assess severity
of symptoms. All 12 compounds investigated were reported to be superior to placebo, but this has only
been replicated for benzodiazepines and chlormethiazole. Further research using better methods is
required to allow comparison of different drugs in the treatment of alcohol withdrawal symptoms. On the
evidence available, a long-acting benzodiazepine should be the drug of first choice.
Table 1. Physiological changes in the acute alcohol history of serious withdrawal symptoms, such as
withdrawal phase seizures or delirium tremens, are clearly in need of
Neurotransmitters drug treatment, but criteria for predicting those
Raised: noradrenaline, acetylcholine, dopamine cases which will benefit from medication have not
Decreased: GABA, 5-HT been clearly defined, even among inpatients
Receptor sensitivity (Shaw, 1995).
Increased: NMDA
Decreased: GABA The merits of any drug treatment need to be
Endocrine considered in the light of evidence for the
Raised antidiuretic hormone, aldosterone, effectiveness of non-pharmacological approaches.
corticotropm-releasing factor, growth hormone Whitfield et al. (1978) successfully treated 1024
Vitamins of 1114 (91.8%) alcoholic inpatients without
Decreased: B h B2, B6, B12, folic acid
Electrolytes and glucose drugs. Staff, all college graduates, were 'given
Low: H + , Mg r + , Ca 2+ , Zn2+, K + , PO42~, HCO3", basic medical instruction' and trained to 'reassure
glucose and relate to disturbed alcoholics . . . restore
familiar surroundings . . . be authoritative (to
Adapted from Glue and Nutt (1990) and Lieber (1991).
enable patients take control of their treatment)'
within a specialist alcohol unit. Ninety patients
(8.2%) were considered to be sufficiently
drawal syndrome represents the various manifes- 'seriously ill' to require medication and were
tations of a single process, or the common sent on to a hospital. There was one case of
pathways of several abnormalities which com- delirium tremens and 12 seizures among the
monly occur together. This uncertainty has been remaining 1024 patients. The mean inpatient stay
reflected in the treatments employed. It is now was 8 days. On average, non-pharmacological
thought that chronic alcohol use causes alterations treatment was required for only 2 days of the stay.
in several neurophysiological parameters to com- The authors were unable to identify characteristics
pensate for chronic central nervous system which distinguished the group requiring more
depression. Following cessation there is an over- intensive treatment before the development of
correction of these changes leading to withdrawal seizures or delirium tremens. The major metho-
symptoms (Sellers and Kalant, 1976). Some of the dological weaknesses of the study were failure to:
physiological changes which have been described (1) use recognized diagnostic criteria; (2) define
are shown in Table 1. The overall effect is that of the study group adequately; (3) use a rating scale
rebound neuronal and biochemical overactivity for severity of withdrawal symptoms; (4) define
following the prolonged depression of activity 'seriously ill'. The study is noteworthy for the
caused by alcohol. Disturbed electrolyte and
vitamin levels may reflect poor dietary intake
during the period of alcohol abuse.
Table 2. Clinical trial quality rating scale
TREATMENT OF ALCOHOL WITHDRAWAL
(a) Degree to which randomization was truly blind
(b) Inclusion of data from subjects who subsequently
The treatment of alcohol withdrawal symptoms withdrew from the study
has tended to follow the prevailing theory as to (c) Degree to which assessors were blind to the treatment
their aetiology. Inevitably the great majority of allocation
alcohol withdrawal episodes occur with no (d) Whether subjects were assessed to determine if they
medical supervision and the majority of medically had accurately guessed their treatment status
(e) Statement of criteria for improvement
supervised alcohol detoxifications occur in non- (f) Use of multiple informants for assessment of outcome
specialist settings, such as general medical and (g) Method of determining dose of drug
general psychiatry wards or, increasingly, at home (h) Whether concurrent treatment was held constant
(Shaw, 1995). Most episodes of alcohol with- (i) Length of baseline observation
drawal do not require sedative medication. Those (j) Control for previous treatment
(k) Control for co-morbidity
individuals experiencing objectively observable
withdrawal symptoms, and those with a past Adapted from Chalmers et al. (1981).
DRUG TREATMENT OF ALCOHOL WITHDRAWAL 105
number of patients studied and the radical identified that included at least one of the drugs
approach taken. The results suggest that placebo that had been subjected to randomized, double-
control groups are required in any evaluation of blind placebo-controlled studies. Although not
drug treatment efficacy if high-risk individuals are analysed in depth, they are presented in the
excluded. Results section. The remaining 15 trials were
The drug with the longest history of use and either open trials or comparison studies in which
most widely used by drinkers for alleviation of none of the compounds had been subjected to
withdrawal symptoms is alcohol itself. It has been double-blind placebo-controlled studies. These are
estimated that > 150 different drugs have been not described.
used to treat alcohol withdrawal symptoms during
the past 30 years (Litten and Allen, 1991). Perhaps RESULTS
the most significant achievement of modern
management of alcohol withdrawal has been to Table 3 describes briefly the 14 trials that were
decrease the mortality from 15% in the 1960s of a randomized, double-blind placebo-controlled
(Victor, 1966) to <2% (Guthrie, 1989). However, design. Table 4 describes, more briefly, the 22
factors other than advances in drug treatment, such randomized, double-blind controlled trials which
as improvement in the overall health and nutri- did not include a placebo group but which
tional status of Western populations, are likely to included one or more of the drugs which had
have been of equal or even greater significance. also been investigated using a placebo-controlled
This review of treatment research was con- design. The results show mainly efficacy data, as
ducted to update that carried out by Moscowitz et few trials published safety data to allow detailed
al. (1983), to determine whether or not more comparison. The trials are grouped according to
recent clinical research had learned from the the drug being studied. Overall quality scores
methodological mistakes of the past and to see if ranged from 8/33 to 22/33 (mean = 13.8). Studies
clearer guidance could now be given on the most with the highest quality designs generally had the
appropriate treatment of the alcohol withdrawal smallest sample sizes.
syndrome.
Benzodiazepines
METHODS Benzodiazepine drugs are used as anxiolytics,
hypnotics, premedication for surgery, muscle
A computer-assisted literature search (Medline) relaxants and anticonvulsants. Benzodiazepines
using key words (alcohol withdrawal, detoxifica- act by potentiating GABA acivity and it is thought
tion and treatment), plus manual cross-reference that their action in the withdrawal period is related
search of articles, review articles and contempor- to this effect.
ary text books, identified 51 trials of pharmaco- Almost as soon as the prototypes were launched
logical treatment for alcohol withdrawal in the late 1950s and early 1960s, trials were
symptoms. Fourteen trials of double-blind pla- performed to assess the efficacy of benzodi-
cebo-controlled design were identified and scored azepines in the treatment of alcohol withdrawal
for quality of design using a modified version of a symptoms. One of the first large trials of
scale developed by Chalmers et al. (1981). The chlordiazepoxide was published in the British
scale comprises 11 aspects of study design and Medical Journal in 1965 (Sereny and Kalant,
quality and is shown in Table 2. Each item is 1965). On the basis of these early trials chlordia-
scored on a 4-point scale, 0 indicating that the zepoxide and diazepam have become the favoured
paper failed to mention anything to enable that treatment in the USA and vie for the top position
criterion to be rated, a score of three indicating a with chlormethiazole in Europe.
'textbook' description of that criterion being Diazepam was launched in 1961 and is the most
satisfied. Only the source paper was scored, so widely used drug in Europe whereas chlordiazep-
that a study may score 0 on some criteria, because oxide has been considered the drug of choice for
it referred only to a previous description of alcohol withdrawal in the USA. The major
method with no further elaboration. differences are the superior anticonvulsant effect
Twenty-two further comparison trials were of diazepam and the claimed greater safety of
o
Table 3. Summary of randomized, double-blind and placebo-controlled trials of drugs in the treatment of the alcohol withdrawal syndrome
Quality No. of Inclusion/exclusion Additional
Study score Drugs Dose patients criteria Measurements medication Results
Sercny and Kalent (1965) 16 Promazine 50/100 mg 58 Male IP volunteer, no Doctor's observation Only if DTs 4fit.swith PZ & I DT, PZ = CDP for
Chlordiazepoxide 25/50 mg non-alcoholic organic Tremometer sleep, PZ decreased BP > CDP.
lesions Galvanometer CDP •+• PZ better than placebo
Sellers el al (1983) 10 Diazepam 20 mg/ 50 IP, CIWA > 20 CIWA-A hourly Phenytoin if DZ more effective than placebo, 90%
2-hourly No HI. OD, 'complex previous WD fits required max. 9 doses, 56% placebo
medical problems', allergy response
Burroughs el al. (1985) 17 Bromocnptine 7.5 mg 71 >80g of ethanol daily SSA, Borg scale CMZ if failed Bromocnptine = placebo = 27%;
Chlordiazepoxide 125 mg for > 5 years IP < 17 on vitamins improved; CDP = CMZ = best
Chlormethiazole 4g Borg scale, 48 h no
psychotropic medicine
Glatt e/n/. (1965) 18 Chlormethiazole 5g 102 All admissions Doctor's 5-point and Phenytoin and CMZ quicker. 40% placebo response
Nil specified patient's 3-point 10 mg CMZ if on sedation in CMZ. doctor and patient
global assessment. 82 placebo noticed difference; higher initial
Sx questionnaire neurological symptom score m placebo r
not shown group
>
Bjorkqvist (1975) 8 Clomdine 0.15 mg 60 NS. consecutive 7-item 4-point scale Phenytoin Clonidine faster relief subjectively and on
self-referral on Monday/ Patient 38-item self- 'hypnotic' required less chlorpromazine PZ
Tuesday, 20-60 year male rating (not shown) pmCPZ Placebo group had higher previous
No chronic or severe acute Tremor measure history of fit;*
medical illness
Wilkinsefa/ (1983) 16 Clonidine 5ug/kg IP alcoholic. 3/6 WD Vital observations. TSA Nil Clonidine better relieving total
symptoms; no Hx of fits, (own version) symptom score and lowers ANS Sx
medical illness anxiety (4 h cross-over study) n
Sellers el al. (1977) 22 Propranolol 60/160 mg 30 Male 21-56, >160g 34-item scale 4 g ethanol per PP best for tremor. HR and BP 03
Chlordiazepoxide
CDP + PP
lOOmg
100+ 60 mg
Ethanol daily >7 days,
>80g/day >2 years
not shown, BP, pulse
Tremometer
day for 1st 5 days,
nil after
Subjectively all = placebo
All more effective than placebo on 9ra
No medical illness or rating scale
contraindication to
medicines
Krau.selw/ (1985) 10 Atenolol 0-100 mg 120 IP <24h, 16-65 years 9-item scale shown BZD Atenolol = shorter in-patient stay
per pulse No substance abuse, 4-point (3 subscales) and fewer sedatives required
severe WD or
contraindication to
medication
Horwitz«a/ (1989) Atenolol As Kraus et al. 180 OP male/as Kraus Kraus 9-item scale Oxazepam Atenolol decreased craving and ANS
(1985) No WD symptoms craving VAS symptoms
37% failure rate on Atenolol
Placebo group more previous DTs and
fits, longer Hx of use
Bjorkqvisl el al (1976) Carbamazepine 800 me 100 OP, 'seeking help 15-item 3-point scale not Sedatives 64% of both groups successful
cooperative", >3 day shown, BP. HR CBZ faster relief; 18 drop-outs in both;
drinking Patient global VAS 11 patients with side-effect.s in CPZ
No drug abuse, medical group
illness
Seller* el al (1976) 19 Lilhium 900 mg Male, > 160 g ethanol EEG, tremometer Nil Lithium better than placebo in
daily Motor tracking tabk symptom relief subjectively
No liver disease, medical 34-nem scale + 17-Uem
illness, contraindication to question
lithium or psychiatric Bloods
illness
Borg and Wcinholt (1982) 8 Bromocnpline 7 5 mg 60 Male 24-71 years, IP, 6-item 6-point scale BZD, CBZ Bromocripline relieved all symptoms
'gamma alcoholic' FSCL, global assessment Dixyrazme 8 drop-outs
No exclusion specified Blood prolactin Lower symptom score of bromoenptine
group at start
Gallimbem rial. (1989) 13 GHBA 50 mg/kg 23 DSM-III WD 6-item 4-point scale Nil GHBA good but high rale of side-
No drug abuse, fits, DT, Word fluency effecK, especially dizziness, 7 h trial
medical illness, epileptic
treatment
Sampliner and Iber (1974) 15 Phenytoin 300 mg 157 History of fits Questionnaire CDP No fits with phenytoin
Consecutive IP, 4 week Presence of fits Fits early with placebo
constant intake Bloods 11 in 11 patients
No medical treatment
Key and abbreviations: =: equally effective; ANS = autonomic nervous system; Bloods: liver function tests, urea and electrolytes, and full blood count;
BP = blood pressure; BZD = benzodiazepines; CBZ = carbamazepine; CDP = chlordiazepoxide; C1WA = Clinical Institute Withdrawal Assessment Scale;
CMZ = chlormethiazole; CPZ = chlorpromazine; Dose: is the daily dosage of the drug unless otherwise specified; DT = delirium tremens; DZ = diazepam;
EEG = electroencephalogram; FSCL = Fischer Symptom Check List; GHBA = gamma-hydroxybutyric acid; HI = head injury; HR = heart rate; Hx = past
history; IP = inpatient; NS = no severe withdrawal at onset included; OD = overdose; OP = outpatient; PP = propranolol; PZ = promazine; prn = as re-
quired; SSA = selected severity scale; Sx = symptom; TSA = total severity assessment; VAS = visual analogue scale; WD = withdrawal.
108 D. WILLIAMS and A. J. McBRIDE
Table 4. Studies in which one or more of the drugs has been investigated using a placebo control group
Study Drugs Measurements Results
Chambers and Schulte (1965) Diazepam 4-point scale (not shown) Promazine = diazepam for DT and
Promazine seizures
Promazine better for mild symptoms
Goldbert et al. (1967) Promazine Own doctor's assessment Paraldehyde most effective
Chlordiazepoxide (now shown) Promazine least effective
Paraldehyde
Alcohol
Kaim et al. (1969) Chlorpromazine Nurses scale, mood scale, Chlordiazepoxide best
Chlordiazepoxide global rating scale, Chlorpromazine worst
Hydroxycine doctor's symptom scale Most drop-outs with thiamine
Thiamine (no scale shown) Seizures worst with chlorpromazine
Mild symptoms all equally controlled
Chlorpromazine least effect on major
symptoms
McGrath (1975) Chlormethiazole Own 5-point scale Chlormethiazole better
Chlordiazepoxide (shown) Fewer drop-outs and fewer DT
Thompson et al. (1975) Diazepam Not reported Diazepam: quicker
Paraldehyde Paraldehyde: more untoward events
Palestine and Alatorre (1976) Haloperidol BPRS Haloperidol: better
Chlordiazepoxide 5-point scale (not shown)
Kramp and Rafaelsen (1979) Diazepam Doctor's and nursing Oral barbital better for frank DT
Barbital observations compared to i.m. diazepam
O'Brien et al. (1983) Lorazepam TSA, global ratings Lorazepam = diazepam
Diazepam One adverse event with lorazepam
11 drop-outs not evaluated
Wilson and Vulcano (1985) Alprazolam 7-point semantic scale Alprazolam = chlordiazepoxide
Chlordiazepoxide shown, Beck scale More seizures in alprazolam group
3 DT in each group
Turbridey (1988) Alprazolam Doctor's and patients' Alprazolam = chlormethiazole
Chlormethiazole ratings (not shown) 1 seizure with alprazolam
Chlormethiazole 10% drop-out group
not evaluated
Kolin and Linnet (1981) Alprazolam Doctor's and patients' Alprazolam = diazepam
Diazepam global rating (not shown)
HARS
Baumgartner and Rowan (1987) Clonidine Own alcohol withdrawal Clonidine more effective for
Chlordiazepoxide scale (not shown) autonomic symptoms and as effective
for others
Madden et al. (1969) Chlormethiazole Own 2-point scale (not Chlormethiazole = trifluoperazine
Trifluoperazine shown) More anxiety in chlormethiazole group
Manhem et al. (1985) Clonidine Clonidine = chlormethiazole
Chlormethiazole Borg 4-point scale DT in both groups
Robinson et al. (1989) Clonidine Chlormethiazole more effective
Chlormethiazole Own scale (not shown) Higher drop-out rate for clonidine
Poutanen (1979) Carbamazepine Carbamazepine effective for all
Own scale (shown) symptoms. No seizures
Ritola and Malinen (1981) Chlormethiazole Own scale (shown) Carbamazepine = chlormethiazole for
Carbamazepine VAS symptoms
More drop-outs with chlormethiazole
More side-effects with carbamazepine
DRUG TREATMENT OF ALCOHOL WITHDRAWAL 109
Table 4. (continued)
Study Drugs Measurements Results
Agricola et al. (1982) Carbamazepine 3-point scale (not shown) Carbamazepine better
Tiapride VAS Quicker for fear and hallucinations
Flygenring et al. (1984) Carbamazepine Own 5-point scale Carbamazepine = barbital
Barbital (shown)
Malcolm et al. (1989) Oxazepam CIWA, BDI, global scale, Carbamazepine = oxazepam,
Carbamazepine anxiety inventory including drop-out rate
Stuppaeck et al. (1992) Oxazepam CIWA-A, global scale, Carbamazepine = oxazepam for
Carbamazepine self-rating scale symptom relief days 1-5
Carbamazepine better days 6-7
Borg and Weinholt (1980) Apomorphine 6-point scale (shown) Bromocriptine better after day 5
Bromocriptine especially for tremor
No side-effects
Key and abbreviations: =: equally effective; BDI = Beck Depressive Inventory, BPRS = brief psychiatric rating scale;
CIWA = Clinical Institute Withdrawal Assessment Scale; DT = delirium tremens; HARS = Hamilton Anxiety Rating
Scale; i.m. = intramuscular; TSA = total severity assessment; VAS = visual analogue scale.
each group. Eleven of the carbamazepine group Gamma-hydroxybutyric acid. The most recent
suffered side-effects such as dizziness. drug to be investigated in the treatment of alcohol
Phenytoin. In a randomized, double-blind withdrawal states is gamma-hydroxybutyric acid
placebo-controlled trial, Sampliner and Iber (GHBA). This is a normal constituent of mammal
(1974) gave phenytoin 100 mg three times daily, brain found especially in the hypothalamus and
in addition to unspecified chlordiazepoxide basal ganglia. It is thought to be a neurotransmit-
regimes, in the prevention of withdrawal seizures ter, having its own specific receptor sites. It is
in 150 patients with a past history of fits. No used in the treatment of narcolepsy, as it decreases
seizures were seen in the 78 patients given rapid eye movement (REM) sleep. It has been
phenytoin, whereas 11 of 77 patients given proposed that GHBA may be of use in withdrawal
placebo suffered one seizure each. states because REM sleep is known to be
It has been suggested that any anticonvulsant increased. In a randomized, double-blind pla-
would exert a similar protective effect for the cebo-controlled study of 23 patients, GHBA was
group of patients at high risk of fits (Saunders, shown to decrease tremor, sweating, nausea,
1987) and that in most cases a sufficiently high depression, anxiety and restlessness occurring
dose of a benzodiazepine or chlormethiazole is during alcohol withdrawal in comparison with
adequate to prevent seizures (Edwards, 1987). placebo (Gallimberti et al., 1989). GHBA caused
prominent side-effects, particularly 'dizziness',
Other drugs not further defined, which affected seven of the
Lithium. Sellers et al. (1976) postulated that 11 GHBA-treated patients in the first 2 days of the
lithium would lessen the activity of the sodium/ trial.
potassium ATPase pump, which is increased in
alcohol withdrawal. In a double-blind placebo- DISCUSSION
controlled trial on 18 patients with mild symp-
toms, nine patients who commenced lithium Comparison of the randomized, double-blind
0.3 mg three times daily prior to withdrawal had placebo-controlled trials described in this paper is
subjectively decreased symptoms. There was no difficult due to methodological problems. Defini-
change in objective measurements of tremor or tion of alcohol dependence or abuse ranged from
vital signs in these patients. The effect was only DSM-IIIR to Jellinek gamma type, whilst eight of
present if treatment was commenced prior to the 14 studies simply used the term 'alcoholic'
abstaining from alcohol. No other treatment was with no further elaboration. In addition to the
given. possible diversity in sample selection that this
Bromocriptine. Alcohol is known to activate implies, comparison is further hampered by the
central dopamine, therefore possibly creating a failure to use a single withdrawal symptom rating
period of dopamine receptor subsensitivity in the scale. Of the 14 scales used, only five had been
withdrawal period. Bromocriptine is a dopamine previously published and each of these was used in
receptor agonist, primarily used in reproductive only one of the 14 studies.
disorders, Parkinson's disease and acromegaly. If the studies are difficult to compare, the
In a randomized, double-blind placebo-con- methodological quality of most studies adds to the
trolled trial, bromocriptine was found to have a difficulties of the reviewer. Major failings in the
significant effect on anxiety, restlessness, depres- studies were commonplace. Few papers recorded
sion, tremor, nausea and sweating in withdrawal details of inclusion and exclusion criteria or
states, when compared with placebo (Borg and revealed the proportion of the proposed study
Weinholt, 1982). Interpretation of results is group thereby excluded. If 'severe' problems were
complicated by all patients having been prescribed excluded, severity was not clearly defined. Sample
benzodiazepines and carbamazepine, in varying numbers were usually small. There was a general
doses, in addition to the study medication. failure to consider or monitor treatment compli-
The therapeutic effect of bromocriptine was ance, and to control for previous treatment or co-
further questioned by Burroughs et al. (1985) who morbidity. Complex drug regimes, in addition to
found it to be significantly inferior to chlormethia- the trial drug, including the use of drugs known to
zole and chlordiazepoxide. be effective in the treatment of alcohol withdrawal
112 D. WILLIAMS and A. J. McBRIDE
symptoms, were common. compounds (Hill and Williams, 1993).
The clinical relevance of the studies is limited Chlormethiazole is effective and is available in
because seven of the 14 trials excluded 'severely intravenous form for rapid sedation of acutely
ill' patients. It is possible that these authors disturbed patients. A major disadvantage of
considered any placebo treatment unethical for chlormethiazole is its potentially lethal interaction
the severely ill, but the work of Whitfield et al. with alcohol, causing respiratory depression and
(1978), discussed earlier in this paper, the high arrest (Mclnnes, 1987). This is particularly
response rates in placebo groups and the low important to bear in mind for outpatients who
incidence of delirium tremens and seizures in all may be at greater risk of drinking whilst on
studies suggest that there are means by which medication. Other potential problems include
these reservations can and should be overcome. depression of the gag reflex (predisposing the
The aims of drug treatment for the alcohol patient to aspiration pneumonia) and confusion.
withdrawal syndrome are to enable the patient to As with benzodiazepines, dependency can be
stop drinking without psychological and physical avoided by confining prescribing to the with-
morbidity or mortality. The effectiveness of any drawal period. However, concerns regarding the
treatment may be measured against the extent to safety of chlormethiazole have led to the manu-
which it achieves these aims. The ideal drug facturer advising outpatient use only in excep-
treatment for the alcohol withdrawal syndrome tional circumstances and the refusal to issue a
should: (a) be effective against all withdrawal safety licence for it in the USA by the Food and
symptoms; (b) be effective as an anticonvulsant; Drug Administration of that country.
(c) be effective in the prevention and treatment of Clonidine and atenolol are ineffective in pre-
delirium tremens and hallucinosis; (d) have a rapid venting major withdrawal effects such as delirium
onset of action; (e) have an easily adjusted dosage; tremens and have no anticonvulsant properties;
(f) be available in oral and injectable forms; (g) they can only be considered as possible adjunctive
prevent craving and minimize short-term relapse; treatments for the suppression of sympathetic
(h) have a wide safety range; (i) have no side- nervous system overactivity (Brewer, 1995) and
effects; (j) have no interactions with alcohol; (k) possibly in the reduction of craving during with-
not be liable to abuse. drawal.
The drugs described in this review have not Of the other drugs, carbamazepine may yet be
been equally or systematically tested against most demonstrated to have the most important role to
of these criteria. What follows is a summary of play. The advantages of carbamazepine are that it
what can reasonably be extracted from the is effective in severe alcohol withdrawal syn-
published literature. drome, including delirium tremens, and is well
Benzodiazepines are superior to placebo in the tolerated. Carbamazepine does not interact with
relief of alcohol withdrawal symptoms apart from alcohol, is not contraindicated in cirrhosis and
hallucinosis, have a cleaner side-effect profile may have an effect on the kindling process,
compared with all other drugs tested (Moscowitz thereby protecting against further withdrawal
et al., 1983) and are safe in the high doses often episodes (Ballenger and Post, 1984). Whether
required in delirium tremens (Woo and Greenblatt, this last action is common to other anticonvulsants
1979). Diazepam is available in oral, rectal and is not known. The disadvantages of carbamaze-
intravenous forms. The main disadvantage of the pine are the potentially serious side-effects,
benzodiazepines is the risk of subsequent depen- including the small risk of potentially fatal
dency, although this should be avoided if use is haematological complications, and the higher
confined to the withdrawal period. Side-effects relative cost compared to benzodiazepines. All
and interactions with other central nervous system other anticonvulsants share the risk of side-effects
depressants, particularly alcohol, which may and it has been suggested that these agents may
rarely cause apnoea are more likely in the elderly. actually increase the incidence of seizures during
Care should also be taken when commencing withdrawal (Hillbom and Hjelm-Jager, 1984).
treatment in those with hepatic impairment None of the other new agents has proved to be
especially if using long-acting compounds. Seiz- superior to the older drugs. None is of proven use
ures are more likely to occur with short-acting in severe withdrawal states, and all are much more
DRUG TREATMENT OF ALCOHOL WITHDRAWAL 113
Hill, A. and Williams, D. (1993) Hazards associated Fagerstrom, R. M. and Smith, H. (1983) Deficiencies
with use of benzodiazepines in alcohol detoxifica- of clinical trials of alcohol withdrawal. Alcoholism:
tion. Journal of Substance Abuse Treatment 10, Clinical and Experimental Research 7, 42-46.
449^51. O'Brien, J. E., Meyer, R. E. and Thomas, D. C. (1983)
Hillbom, M. and Hjelm-Jager, M. (1984) Should alcohol Double blind comparison of lorazepam and diaze-
withdrawal seizures be treated with anti-epileptic pam in the treatment of acute alcohol abstinence
drugs. Ada Neurologica Scandinavica 69, 39^4-2. syndrome. Current Therapeutic Research 34,
Horwitz, R., Gottlieb, L. D. and Kraus, M. L. (1989) 825-831.
The efficacy of atenolol in the outpatient manage- Palestine, M. L. and Alatorre, E. (1976) Control of acute
ment of the alcohol withdrawal syndrome. Archives alcohol withdrawal symptoms. Current Therapeutic
of Internal Medicine 149, 1089-1093. Research 20, 289-299.
Isbell, H., Fraser, H. R, Wilder, A., Beleville, R. E. and Poutanen, P. (1979) Experience with carbamazepine in
Eisenman, A. J. (1955) An experimental study of the treatment of withdrawal symptoms in alcohol
etiology of 'rum fits' and delirium tremens. Quar- abusers. British Journal of Addiction 74, 201-204.
terly Journal of Studies on Alcohol 16, 1-33. Ritola, E. and Malinen, L. (1981) A double blind
Kaim, S. C , Klett, C. J. and Rothfield, B. (1969) comparison of carbamazepine and chlormethiazole
Treatment of alcohol withdrawal symptoms. A in treatment of alcohol withdrawal syndrome. Ada
comparison of four drugs. American Journal of Psychiatrica Scandinavica 64, 254-259.
Psychiatry 125, 54-59. Robinson, B. J., Robinson, G. M., Maling, T. J. B. and
Kolin, I. S. and Linnet, D. I. (1981) Double blind Johnson, R. H. (1989) Is clonidine useful in
comparison of alprazolam and diazepam for sub- treatment of alcohol withdrawal? Alcoholism: Clin-
chronic withdrawal from alcohol. Journal of Clinical ical and Experimental Research 13, 95-98.
Psychiatry 42, 169-173. Sampliner, R. and Iber, F. L. (1974) Diphenhydantoin
Kramp, P. and Rafaelsen, O. J. (1979) Delirium control of withdrawal seizures. Journal of the
tremens. A double blind comparison of diazepam American Medical Association 230, 1430-1432.
and barbital treatment. Ada Psychiatrica Saunders, J. B. (1987) Drug treatment in alcoholism. In
Scandinavica 58, 174-190. Antimanics, Anticonvulsants and Other Drugs in
Kraus, M. L., Gottlieb, L., Horwitz, R. and Anscher, M. Psychiatry, Burrow, G. D. and Norman, T. R. eds,
(1985) Randomised clinical trial of atenolol in Vol. 4, pp. 343-369. Elsevier, Amsterdam.
patients with alcohol withdrawal. New England Schuckit, M. A. (1995) Alcohol and depression, a
Journal of Medicine 313, 905-909. clinical perspective. Ada Psychiatrica Scandinavica
Lieber, C. S. (1991) Hepatic, metabolic and toxic effects 377 (Suppl.), 28-32.
of ethanol. Alcoholism: Clinical and Experimental Serfaty, M. and Masterton, G. (1993) Fatal poisonings
Research 15, 573-592. attributed to benzodiazepines in Britain during the
Litten, R. Z. and Allen, R. (1991) Pharmacotherapies for 1980's. British Journal of Psychiatry 163, 386-393.
alcoholism: promising agents and clinical issues. Sellers, E. M. and Kalant, H. (1976) Alcohol intoxica-
Alcoholism: Clinical and Experimental Research 15, tion and withdrawal. New England Journal of
620-633. Medicine 294, 757-762.
Lundqvist, G. The clinical use of chlormethiazole. Ada Sellers, E. M., Cooper, S. D., Zilm, D. H. and Shanks, C.
Psychiatrica Scandinavica 1996, 42 (Suppl. 92), (1976) Lithium treatment during alcohol withdrawal.
113-114. Clinical Pharmacology and Therapy 20, 199-206.
Madden, J. S., Jones, D. and Frisch, E. P. (1969) Sellers, E. M., Zilm, D. H. and Degani, N. C. (1977)
Chlormethiazole and trifluoperazine in alcohol Comparative efficacy of propranolol and chlordia-
withdrawal. British Journal of Psychiatry 115, zepoxide in alcohol withdrawal. Quarterly Journal
1191-1192. of Studies on Alcohol 38, 2096-2108.
Malcolm, R., Ballenger, J., Sturgis, E. and Anton, R. Sellers, E. M., Naranjo, C. A., Harrison, M., Devenyi,
(1989) Double blind comparison trial comparing P., Roach, C. and Sykora, K. (1983) Diazepam
carbamazepine to oxazepam treatment of alcohol loading. Simplified treatment of alcohol withdrawal.
withdrawal. American Journal of Psychiatry 146, Clinical Pharmacology and Therapy 34, 822-826.
617-621. Sereny, G. and Kalant, H. (1965) Comparative clinical
Manhem, P., Nilsson, L. H., Moberg, A., Wadstein, J. evaluation of chlordiazepoxide and promazine in
and Hokfelt, B. (1985) Alcohol withdrawal: effects treatment of alcohol withdrawal syndrome. British
of clonidine treatment on sympathetic activity. Medical Journal 1, 92-97.
Alcoholism: Clinical and Experimental Research 9, Shaw, G. K. (1995) Detoxification, the use of
238-244. benzodiazepines. Alcohol and Alcoholism 30,
McGrath, S. D. (1975) A controlled study of chlor- 765-770.
methiazole and chlordiazepoxide in treatment of the Stuppaeck, C. H., Miller, E., Pycha, R., Whitworth, A.
acute withdrawal phase of alcoholism. British B., Oberbauer, H. and Fleischhallker, W. W. (1992)
Journal of Addiction 70 (Suppl.), 81-90. Carbamazepine versus oxazepam in the treatment of
Mclnnes, G. T. (1987) Chlormethiazole and alcohol: a alcohol withdrawal. Alcohol and Alcoholism 27,
lethal cocktail. British Medical Journal 294, 592. 153-158.
Moscowitz, G., Chalmers, T. L., Sacks, U. S., Thompson, W. L., Johnson, A. D. and Maddrey, W. L.
DRUG TREATMENT OF ALCOHOL WITHDRAWAL 115
(1975) Diazepam and paraldehyde for treatment of psychoactive drugs. Journal of the American Medi-
severe delirium tremens. Annals of Internal Medicine cal Association 239, 1409-1410.
82, 175-180. Wilkins, A. J., Jenkins, W. J. and Steiner, J. A. (1983)
Turbridy, P. (1988) Alprazolam versus chlormethiazole Efficacy of clonidine in treatment of alcohol with-
in acute alcohol withdrawal. British Journal of drawal state. Psychopharmacology 81, 78-81.
Addiction 83, 581-585. Wilson, A. and Vufcano, B. A. (1985) Double blind trial
Victor, M. (1966) Treatment of alcoholic intoxication of alprazolam and chlordiazepoxide in management
and the withdrawal syndrome. Psychosomatic of acute ethanol withdrawal syndrome. Alcoholism:
Medicine 28, 636-650. Clinical and Experimental Research 9, 23-27.
Victor, M. and Adams, R. (1953) The effect of alcohol Woo, E. and Greenblatt, D. (1979) Massive benzodi-
on the nervous system. Research Publication of the azepine requirements in acute alcohol withdrawal.
Association for Nervous and Mental Disorders 32, American Journal of Psychiatry 136, 821-823.
526-573. World Health Organization (1992) The ICD 10
Whitfield, C. L., Thompson, G., Lamb, A., Spencer, U., Classification of Mental and Behavioural Disorders:
Pfiefer, M. and Browning-Ferrado, M. (1978) Clinical Descriptions and Diagnostic Guidelines.
Detoxification of 1024 alcoholic patients without WHO, Geneva.